Evidence-based Complementary and Alternative Medicine 2013-01-01

Combination Therapy of Sophoraflavanone B against MRSA: In Vitro Synergy Testing.

Su-Hyun Mun, Ok-Hwa Kang, Dae-Ki Joung, Sung-Bae Kim, Yun-Soo Seo, Jang-Gi Choi, Young-Seob Lee, Seon-Woo Cha, Young-Sup Ahn, Sin-Hee Han, Dong-Yeul Kwon

文献索引：Evid. Based. Complement. Alternat. Med. 2013 , 823794, (2013)

全文：HTML全文

摘要

Sophoraflavanone B (SPF-B), a known prenylated flavonoid, was isolated from the roots of Desmodium caudatum. The aim of this study was to determine the antimicrobial synergism of SPF-B combined with antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). MRSA, a multidrug-resistant pathogen, causes both hospital- and community-acquired infections worldwide. The antimicrobial activity of SPF-B was assessed by the broth microdilution method, checkerboard dilution test, and time-kill curve assay. The MIC of SPF-B for 7 strains of S. aureus ranges from 15.6 to 31.25  μ g/mL determined. In the checkerboard method, the combinations of SPF-B with antibiotics had a synergistic effect; SPF-B markedly reduced the MICs of the β -lactam antibiotics: ampicillin (AMP) and oxacillin (OXI); aminoglycosides gentamicin (GET); quinolones ciprofloxacin (CIP) and norfloxacin (NOR) against MRSA. The time-kill curves assay showed that a combined SPF-B and selected antibiotics treatment reduced the bacterial counts below the lowest detectable limit after 24 h. These data suggest that the antibacterial activity of SPF-B against MRSA can be effectively increased through its combination with three groups of antibiotics ( β -lactams, aminoglycosides, and quinolones). Our research can be a valuable and significant source for the development of a new antibacterial drug with low MRSA resistance.